Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC in Autoimmune Encephalitis
NCT07583641Phase 2Not yet recruiting
- Sponsor
- argenx
- Start
- Apr 2027
- Primary completion
- Jul 2030
- Modality
- Antibody Fragments, Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efgartigimod alfa in Autoimmune Encephalitis (AE), sponsored by argenx. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on NCT07583641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583641.